We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia

By LabMedica International staff writers
Posted on 10 Jul 2026

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with heterogeneous biology that complicates prognostication and treatment selection. More...

Genetic testing clarifies many drivers, yet it often fails to explain divergent disease trajectories among patients. Understanding non-genetic mechanisms of gene regulation has become an important diagnostic frontier. A new study shows how epigenetic mapping can stratify AML into biologically meaningful groups.

Karolinska Institutet, in collaboration with Kyoto University, evaluated an epigenetic mapping approach that profiles how accessible DNA is within the cell nucleus to infer which genes may be active. The method captures chromatin accessibility, enabling classification based on gene regulatory states rather than DNA sequence changes. Researchers assessed regulatory patterns to delineate molecular programs that underlie AML heterogeneity and clinical behavior.

The investigation analyzed samples from 1,563 patients in Sweden and Japan. Using measurements of DNA accessibility, the team divided AML into 16 groups with distinct molecular and biological characteristics. The study integrated multiple data types, including gene expression, DNA methylation, and single-cell analyses, to define each group’s patterns of gene regulation, cell differentiation, and disease progression.

Several epigenetically defined groups were more closely associated with patient survival than existing classification systems, indicating added prognostic value. Drug-response profiling across 250 agents revealed group-specific differences in sensitivity that aligned with the epigenetic categories. The authors noted that these findings, published in Nature on July 8, 2026, do not replace current genetics-based systems but can complement them, and that additional studies are needed to validate the results and clarify clinical use.

“Our results show that, based on epigenetic analyses, leukemia can be divided into new biologically relevant subgroups that provide more information than genetic analyses alone,” said Sören Lehmann, professor at the Department of Medicine, Huddinge, Karolinska Institutet.

Related Links
Karolinska Institutet
Kyoto University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Multi-Chamber Washer-Disinfector
WD 390
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.